These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 33457265)

  • 1. Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer.
    Tholomier C; Souhami L; Kassouf W
    Transl Androl Urol; 2020 Dec; 9(6):2920-2937. PubMed ID: 33457265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives.
    Fan X; He W; Huang J
    Transl Androl Urol; 2023 May; 12(5):802-808. PubMed ID: 37305635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
    Arcangeli G; Strigari L; Arcangeli S
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
    Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
    Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis.
    Kim YJ; Byun SJ; Ahn H; Kim CS; Hong BS; Yoo S; Lee JL; Kim YS
    Oncotarget; 2017 Sep; 8(40):68996-69004. PubMed ID: 28978174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.
    El-Achkar A; Souhami L; Kassouf W
    Curr Urol Rep; 2018 Nov; 19(12):108. PubMed ID: 30392150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
    Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer.
    Russell CM; Lebastchi AH; Borza T; Spratt DE; Morgan TM
    Bladder Cancer; 2016 Oct; 2(4):381-394. PubMed ID: 28035319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer.
    Nadal R; Apolo AB; Girardi DM; Hahn NM; Bellmunt J
    Urol Oncol; 2023 Jan; 41(1):27-34. PubMed ID: 34756410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial.
    Yang X; Zhang S; Cui Y; Li Y; Song X; Pang J
    BMC Cancer; 2023 Apr; 23(1):320. PubMed ID: 37024824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bladder preservation using chemoradiation therapy for locally invasive bladder cancer].
    Abe T; Yoshioka T; Sato M; Mori N; Sekii K; Itatani H
    Nihon Hinyokika Gakkai Zasshi; 2011 Jan; 102(1):14-22. PubMed ID: 21520632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of the COVID19 pandemic on the need and timing of second transurethral bladder tumour resection in high-grade non-muscle invasive bladder cancer.
    Vanneste M; van der Heij B; Christiaansen CE; Berendsen CL; Driessen EJM; Bruins HM
    World J Urol; 2023 Aug; 41(8):2173-2178. PubMed ID: 37328699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimodal therapy in muscle invasive bladder cancer management.
    Polo-Alonso E; Kuk C; Guruli G; Paul AK; Thalmann G; Kamat A; Solsona E; Thalmann G; Urdaneta AI; Zlotta AR; Mir MC
    Minerva Urol Nefrol; 2020 Dec; 72(6):650-662. PubMed ID: 33263367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond.
    Sheybaee Moghaddam F; Dwabe S; Mar N; Safdari L; Sabharwal N; Goldberg H; Daneshvar M; Rezazadeh Kalebasty A
    Cancers (Basel); 2024 Sep; 16(19):. PubMed ID: 39409980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer.
    Feldman AS; Kulkarni GS; Bivalacqua TJ; Black PC; Delacroix S; Lerner SP; Kamat AM; Kassouf W
    Urol Oncol; 2022 Oct; 40(10):442-450. PubMed ID: 33642229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.